Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer

Clinical Lung Cancer
Noriyuki MasudaM Fukuoka

Abstract

We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of topotecan when administered weekly to patients with advanced non-small-cell lung cancer. Twelve patients with stage IIIB or IV disease were treated with topotecan by 30-minute intravenous infusion on days 1, 8, and 15 every 4 weeks. The dose was escalated in 2-mg/m2 increments from the starting dose of 4 mg/m2 until the MTD was reached. After the MTD had been reached in previously treated patients, chemotherapy-naive patients were enrolled for treatment at that dose, and the dose was escalated to estimate the MTD in the treatment-naive group. The MTD of topotecan was determined to be 6 mg/m2 in the previously treated group and 8 mg/m2 in the chemotherapy-naive group. All 3 previously treated patients experienced DLT at the 6-mg/m2 dose level. Although only 1 of the 3 previously treated patients experienced DLT (grade 4 neutropenia for > or = 3 days) at the 8-mg/m2 dose level, skipping the topotecan dose on day 15 because of neutropenia was reported in 2 patients. Anorexia and general fatigue were the common nonhematologic toxicities. The recommended do...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T AndohK Okada
Jan 1, 1982·Pharmacology & Therapeutics·N H Holford, L B Sheiner
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·L J van WarmerdamJ H Beijnen
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·H RosingJ H Beijnen
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Jan 1, 1997·British Journal of Cancer·V M HerbenJ H Beijnen
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J von PawelR Gralla
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Sep 27, 2002·The Oncologist·Robert Morris, Adnan Munkarah
Dec 8, 2004·Gynecologic Oncology·Snehal M BhoolaRonald D Alvarez
May 1, 1997·Expert Opinion on Investigational Drugs·J Carmichael, R F Ozols
Jul 5, 2005·Gynecologic Oncology·David M O'MalleyThomas Rutherford
Oct 2, 2007·Gynecologic Oncology·Fadi AbushahinJulian C Schink
Oct 27, 2007·The Oncologist·Mary O'BrienRodryg Ramlau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
N MasudaM Fukuoka
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ranjana AdvaniBranimir I Sikic
© 2021 Meta ULC. All rights reserved